Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hanmi Inks Record Korean Deal, With Boehringer For Cancer Therapy

This article was originally published in PharmAsia News

Executive Summary

Hanmi Pharmaceutical continues to lead South Korean pharma innovators by reaching a series of major licensing out deals. Following the major agreement with Lilly for its oral Bruton's tyrosine kinase inhibitor earlier this year, Hanmi has now inked an even bigger license agreement with Boehringer Ingelheim, for a novel non-small cell lung cancer therapy HM61713 that will beef up the German firm's oncology portfolio.

You may also be interested in...



Korean Pharmas To Highlight Lung Cancer Pipeline Progress At AACR

Several South Korean companies are set to present updates on their growing lung cancer pipelines at a major meeting in Chicago this month, underlining the high unmet needs and strong R&D interest in this area by firms in the country.  

Hanmi’s Case: One Failure Doesn’t Speak For All

Since Boehringer Ingelheim’s u-turn on its lung cancer partnership with Hanmi Pharmaceutical, the South Korean company has seen its stock prices falling and latterly a government investigation. Confidence in the country’s burgeoning drug development industry has taken a hit but there are still plenty of reasons to believe in the country’s R&D engine.

SillaJen Minority Shareholders Unite, Call For Trade Resumption

Faced with the risk of losing their investment from a possible stock delisting amid prosecutors’ probes into company’s management, SillaJen’s individual minority shareholders are demanding the Korea Exchange resume trading of the biotech’s stock, in a rare united move.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID043835

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel